Engineered heart tissues for cardiac safety assessment

This poster presents Ncardia’s bioreactor-produced human iPSC-derived ventricular cardiomyocytes integrated into engineered heart tissues (EHTs), combining scalable cell manufacturing with physiologically relevant contractility testing for translational cardiac safety assessment.

Download it now for a closer look at:

• How Ncyte® vCardiomyocytes are manufactured at scale in controlled stirred-tank bioreactors and incorporated into 3D engineered heart tissues 

• How the MyoPod® and MyoLab® platforms enable real-time assessment of contractile force, tissue dynamics and pharmacological responses

• Functional data showing a robust β-adrenergic response to isoproterenol, including increased peak force and accelerated contraction and relaxation kinetics

• How the engineered tissues demonstrate positive force-frequency behaviour and physiological length-dependent activation

• How scalable hiPSC-vCM manufacturing and 3D contractility testing can be combined to support translational cardiac safety pharmacology workflows